

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P.O. 60 1450 Alexandria, Viginia 22313-1450

NOTICE OF ALLOWANCE AND FEE(S) DUE

25226

7590

06/17/2003

MORRISON & FOERSTER LLP 755 PAGE MILL.RD PALO ALTO, CA 94304-1018 EXAMINER

SPIVACK, PHYLLIS G

ART UNIT CLASS-SUBCLASS

1614

514-458000

DATE MAILED: 06/17/2003

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/020 450	12/14/2001	Guy Michael Miller	346392000900	1698

TITLE OF INVENTION: METHODS FOR THE TREATMENT OF NEURONAL DAMAGE ASSOCIATED WITH CEREBRAL ISCHEMIA

1	APPLN. TYPE	SMALL ENTITY	ISSUE FEE	PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE
	nonprovisional	YES	\$650	\$300	\$950	09/17/2003

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. <u>PROSECUTION ON THE MERITS IS CLOSED.</u> THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE REFLECTS A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE APPLIED IN THIS APPLICATION. THE PTOL-85B (OR AN EQUIVALENT) MUST BE RETURNED WITHIN THIS PERIOD EVEN IF NO FEE IS DUE OR THE APPLICATION WILL BE REGARDED AS ABANDONED.

HOW TO REPLY TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

A. If the status is the same, pay the TOTAL FEE(S) DUE shown above.

B. If the status is changed, pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above and notify the United States Patent and Trademark Office of the change in status, or

If the SMALL ENTITY is shown as NO:

A. Pay TOTAL FEE(S) DUE shown above, or


B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check the box below and enclose the PUBLICATION FEE and 1/2 the ISSUE FEE shown above.

 Applicant claims SMALL ENTITY status. See 37 CFR 1.27.

II. PART B - FEE(S) TRANSMITTAL should be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). Even if the fee(s) have already been paid, Part B - Fee(s) Transmittal should be completed and returned. If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Box ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.



ISSUE FEE

\$650

ART UNIT

1614

(Date)



Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE

Commissioner for Patents Alexandria, Virginia 22313-1450

(703)746-4000

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 4 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Legably mark-up with any corrections or use Block I)

FILING DATE

12/14/2001

SMALL ENTITY

YES

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).

☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.

Q "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required.

APPLICATION NO.

10/020,450

APPLN. TYPE

nonprovisional

(A) NAME OF ASSIGNEE

4a. The following fee(s) are enclosed:

□ Advance Order - # of Copies

☐ Issue Fee

□ Publication Fee

(Authorized Signature)

EXAMINER

SPIVACK, PHYLLIS G

7590

06/17/2003

MORRISON & FOERSTER LLP 755 PAGE MILL RD PALO ALTO, CA 94304-1018

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission. Certificate of Mailing or Transmission I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Box Issue Fee address above, or being facsimile transmitted to the USPTO, on the date indicated below. (Depositor's name) (Signature (Date) FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. Guy Michael Miller 346392000900 1698 TITLE OF INVENTION: METHODS FOR THE TREATMENT OF NEURONAL DAMAGE ASSOCIATED WITH CEREBRAL ISCHEMIA PUBLICATION FEE TOTAL FEE(S) DUE DATE DUE \$950 09/17/2003 CLASS-SUBCLASS 514-458000 2. For printing on the patent front page, list (1) the names of up to 3 registered patent attorneys or agents OR, alternatively, (2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed. 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. Inclusion of assignee data is only appropriate when an assignment has been previously submitted to the USPTO or is being submitted under separate cover. Completion of this form is NOT a substitute for filing an assignment. (B) RESIDENCE: (CITY and STATE OR COUNTRY) Please check the appropriate assignee category or categories (will not be printed on the patent) ☐ individual ☐ corporation or other private group entity ☐ government 4b. Payment of Fee(s): ☐ A check in the amount of the fee(s) is enclosed. ☐ Payment by credit card. Form PTO-2038 is attached. ☐ The Commissioner is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number ______(enclose an extra copy of this form). Commissioner for Patents is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above.

NOTE; The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office. This collection of information is required by 37 CFR 1.311. The information is required to Ihis collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMIT THIS FORM WITH FEE(S)



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vigania 22313-1450

DATE MAILED: 06/17/2003

APPLICATION NO), FI	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO	CONFIRMATION NO.	
10/020,450		12/14/2001	Guy Michael Miller	346392000900	1698	
25226	7590	06/17/2003		EXAM	INER	
MORRISON & FOERSTER LLP				SPIVACK, PHYLLIS G		
755 PAGE MI	LL RD		•			
PALO ALTO	CA 94304-	1018		ART UNIT	PAPER NUMBER	
				1614		

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b) (application filed on or after May 29, 2000)

The patent term adjustment to date is 0 days. If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the term adjustment will be 0 days.

If a continued prosecution application (CPA) was filed in the above-identified application, the filing date that determines patent term adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) system. (http://pair.uspto.gov)

Any questions regarding the patent term extension or adjustment determination should be directed to the Office of Patent Legal Administration at (703)305-1383.



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Viginia 22313-1450

APPLICATION NO.	1	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/020,450		12/14/2001	Guy Michael Miller	346392000900	1698	
25226	7590	06/17/2003		EXAMIN	ER	
MORRISON & FOERSTER LLP				SPIVACK, PHYLLIS G		
755 PAGE MILL RD PALO ALTO, CA 94304-1018				ART UNIT	PAPER NUMBER	
	UNITED STATES			1614		
				DATE MAILED: 06/17/2003		

Notice of Fee Increase on January 1, 2003

If a reply to a "Notice of Allowance and Fee(s) Due" is filed in the Office on or after January 1, 2003, then the amount due will be higher than that set forth in the "Notice of Allowance and Fee(s) Due" since there will be an increase in fees effective on January 1, 2003. See Revision of Patent and Trademark Fees for Fiscal Year 2003; Final Rule, 67 Fed. Reg. 70847, 70849 (November 27, 2002).

The current fee schedule is accessible from: http://www.uspto.gov/main/howtofees.htm,

If the issue fee paid is the amount shown on the "Notice of Allowance and Fee(s) Due," but not the correct amount in view of the fee increase, a "Notice to Pay Balance of Issue Fee" will be mailed to applicant. In order to avoid processing delays associated with mailing of a "Notice to Pay Balance of Issue Fee," if the response to the Notice of Allowance and Fee(s) due form is to be filed on or after January 1, 2003 (or mailed with a certificate of mailing on or after January 1, 2003), the issue fee paid should be the fee that is required at the time the fee is paid. If the issue fee was previously paid, and the response to the "Notice of Allowance and Fee(s) Due" includes a request to apply a previously-paid issue fee to the issue fee now due, then the difference between the issue fee amount at the time the response is filed and the previously paid issue fee should be paid. See Manual of Patent Examining Procedure, Section 1308.01 (Eighth Edition, August 2001).

Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at (703) 305-8283.

Notice of Allowability

Application No. 10/020,450 Applicant(s)

Miller et al.

Examiner

Phyllis G. Spivack

Art Unit 1614



The MAILING DATE of this communication appears on the cover sheet with the correspondence address
All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.
1. X This communication is responsive to the Amendment filed May 22, 2003 .
2. X The allowed claim(s) is/are 1-62
3. X The drawings filed on <u>Dec 14, 2001</u> are accepted by the Examiner.
4. Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).
a) 🗌 All b) 🗎 Some* c) 🗀 None of the:
1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No
3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).
*Certified copies not received:
5. X Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
(a) The translation of the foreign language provisional application has been received.
6. Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.
7. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
8. CORRECTED DRAWINGS must be submitted.
(a) \square including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
1) 🗆 hereto or 2) 🗆 to Paper No
(b) ☐ including changes required by the proposed drawing correction filed, which has been approved by the examiner.
(c) ☐ including changes required by the attached Examiner's Amendment/Comment or in the Office action of Paper No
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the top margin (not the back) of each sheet. The drawings should be filed as a separate paper with a transmittal letter addressed to the Official Draftsperson.
9. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.
Attachment(s)
1 Notice of References Cited (PTO-892) 2 Notice of Informal Patent Application (PTO-152)
3 Notice of Draftsperson's Patent Drawing Review (PTO-948) 4 Interview Summary (PTO-413), Paper No
5 ☑ Information Disclosure Statement(s) (PTO-1449), Paper No(s)
7 Li Examiner's Comment Regarding Requirement for Deposit of Biological 8 X Examiner's Statement of Reasons for Allowance Material
9 Other

Application/Control Number: 10/020450 Page 2

Art Unit: 1614

REASONS FOR ALLOWANCE

The following is an Examiner's statement of Reasons for Allowance:

An Information Disclosure Statement filed May 22, 2003, Paper No. 17, is acknowledged and has been reviewed.

Claims 1-62 remain under consideration.

In the last Office Action claims 1-3, 8-32 and 51-62 were rejected under 35 U.S.C. 103 as being unpatentable over Fryer, M.J., <u>Nutritional Neuroscience</u>. It was asserted Fryer teaches the administration of tocopherols for the treatment of both neuronal damage and cerebral ischemic conditions. Gamma-tocopherol is disclosed to be far superior to alpha tocopherol in the detoxification of peroxynitrite, an inflammatory nitrogen oxide that induces lipid peroxidation, and is a retrograde messenger generated in post-synaptic neurons.

Applicants argue Fryer does not suggest that the disclosed biochemical activity is predictive of efficacy *in vivo*, or, of efficacy in reducing neuronal damage related to a cerebral ischemic condition in a mammal.

Although it is the Examiner's position that Fryer provides initial motivation to one skilled in the art to modify the teaching of the reference and administer gamma tocopherol in place of alpha tocopherol with a reasonable expectation of success in the treatment of ischemia-induced neuronal damage, all claim limitations are not taught or suggested. Further, conflicting or

Application/Control Number: 10/020450 Page 3

Art Unit: 1614

equivocal results are shown with respect to concentrations and efficiency of gamma tocopherol.

Accordingly, the rejection of record under 35 U.S.C. 103 is withdrawn.

Claims 1-62 are allowed in view of the contemporary knowledge of the art.

Any comments considered necessary by Applicants must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Phyllis Spivack whose telephone number is (703) 308-4703.

June 15, 2003

PHYLLIS SPIVACK PRIMARY EXAMINER

Phyllis Spivack